A Phase 1 Randomized, Placebo-Controlled, Blinded Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ARC-001 in Participants Undergoing Third Molar Extraction
Latest Information Update: 26 Aug 2026
At a glance
- Drugs ARC 001 (Primary)
- Indications Postoperative pain
- Focus Adverse reactions; First in man
- Sponsors Arcato Laboratories
Most Recent Events
- 19 Aug 2026 Primary endpoint (Safety and Tolerability) has been met.
- 19 Aug 2026 Results presented at Arcato Laboratories media release.
- 21 Mar 2025 New trial record